- Home
- DAWN vs FINS Comparison
DAWN vs FINS Comparison
Compare DAWN & FINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- FINS
- Stock Information
- Founded
- DAWN 2018
- FINS 2019
- Country
- DAWN United States
- FINS United States
- Employees
- DAWN N/A
- FINS N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- FINS Finance/Investors Services
- Sector
- DAWN Health Care
- FINS Finance
- Exchange
- DAWN Nasdaq
- FINS Nasdaq
- Market Cap
- DAWN 624.8M
- FINS 443.4M
- IPO Year
- DAWN 2021
- FINS N/A
- Fundamental
- Price
- DAWN $7.11
- FINS $13.28
- Analyst Decision
- DAWN Strong Buy
- FINS
- Analyst Count
- DAWN 7
- FINS 0
- Target Price
- DAWN $27.86
- FINS N/A
- AVG Volume (30 Days)
- DAWN 960.1K
- FINS 78.0K
- Earning Date
- DAWN 10-29-2025
- FINS 01-01-0001
- Dividend Yield
- DAWN N/A
- FINS 9.97%
- EPS Growth
- DAWN N/A
- FINS N/A
- EPS
- DAWN N/A
- FINS N/A
- Revenue
- DAWN $187,638,000.00
- FINS N/A
- Revenue This Year
- DAWN $12.56
- FINS N/A
- Revenue Next Year
- DAWN $48.02
- FINS N/A
- P/E Ratio
- DAWN N/A
- FINS N/A
- Revenue Growth
- DAWN 2190.50
- FINS N/A
- 52 Week Low
- DAWN $5.64
- FINS $11.61
- 52 Week High
- DAWN $16.76
- FINS $12.57
- Technical
- Relative Strength Index (RSI)
- DAWN 51.59
- FINS 52.10
- Support Level
- DAWN N/A
- FINS $13.20
- Resistance Level
- DAWN $7.58
- FINS $13.55
- Average True Range (ATR)
- DAWN 0.25
- FINS 0.12
- MACD
- DAWN -0.32
- FINS 0.00
- Stochastic Oscillator
- DAWN 91.92
- FINS 34.52
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.